Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.38 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27699988 | 0.85 | HRH3 (0.49) | HRH3GLADAOCYP19A1CYP11B1 | |
| SCHEMBL2153847 | 0.80 | HRH3 (0.59) | HRH3MPOGLADAOIDH1 | |
| SCHEMBL4196662 | 0.74 | HRH3 (0.54) | HRH3MPOGLAIDH1CYP19A1 | |
| SCHEMBL10516151 | 0.74 | MAOB (0.46) | HRH3CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28173296 | 0.74 | DAO (0.53) | MPODAO | |
| SCHEMBL7489906 | 0.72 | HRH3 (0.52) | HRH3MPO | |
| SCHEMBL1108477 | 0.72 | TAAR1 (0.50) | HRH3DAO | |
| SCHEMBL2154019 | 0.72 | GLA (0.53) | HRH3GLACYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28448952 | 0.71 | DAO (0.51) | HRH3GLADAOCYP19A1CYP11B1 | |
| SCHEMBL18641329 | 0.70 | HRH3 (0.50) | HRH3GLAIDH1CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | APOB, APOL1, CETP | HRH3 2721/4885CYP2D6 2199/4885MPO 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.